Genmab
Aktiesnakken
Genmab
TESLA
Bavarian Nordic
NOVO
Ennogie
OLIE OG GAS
Amerikanske aktier
AMBU
Biotek-snakken
Vestas
Shipping
GN Store Nord
Pharma
Hansa Biopharma
BITCOIN
Banker og Finans
Grønne Aktier
Medico
Zealand Pharma
Chemometec
EL-BILER
Gubra
Laks
Embla Medical
30/4 21:04 af Raun |
Er det korrekt at JnJ har hele 2024 til at gøre brug af sin opt in?...... Og er det kor
rekt at der vil komme yderligere data på CD38, her i løbet af andet kvartal?
| |
30/4 19:48 af Pensionisten |
ADS'en har det lidt skidt lige nu - nede med 2,94%
| |
30/4 18:57 af JKY_VH |
Alt godt kommer til den der har tålmodigheden til at vente;-)
| |
30/4 18:33 af Vitus |
Godt spørgsmål, men jeg er overbevist om, at mange har mistet tålmodigheden !
| |
30/4 17:47 af lahn1 |
Hvorlænge skal man havde været aktionær i Gmab for at kunne kalde sig for En Tålmodig Invester ?
| |
30/4 15:21 af E L |
TECVAYLI available in Spain from may1 (link)
| |
30/4 14:14 af E L |
New trial - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy (HexaBody-OX40) (link)
| |
30/4 14:12 af E L |
it seems no patients were recruited yet, so the costs should be limited
| |
30/4 14:11 af E L |
the new Endometrial Cancer trial with GEN1046 will not continue; due to [Enrollment challenged by availability of other treatment options] (link)
| |
30/4 12:41 af E L |
Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors (link) -Bio-Techne is a leading supplier of high quality and innovative tools for Life Science Research, Therapeutic Manufacturing and Clinical Diagnostics.
| |
30/4 12:40 af E L |
no, i don't. would be fun indeed to look at these same analysts forecasts for that
| |
30/4 12:18 af GeorgeBest |
Thanks E L. Do you know how the forecasters see the market share split between epco versus glofi/monesu? 50/50?
| |
30/4 12:14 af Raun |
Hvor er det da ved at være pinligt for Jyske Bank.... - Hold nu op, hvor har de gentaget sig selv mange gange igennem de seneste måneder.... - De må have et ordentlig læs aktier de meget gerne vil af med :-)
| |
30/4 12:01 af lahn1 |
Det skrev Jyske også for 3 mdr siden
| |
30/4 11:51 af w |
jyske undrer sig også over fald ovenpå positive nyheder
| |
30/4 11:43 af royal |
KYSO. att.: Helge: "Den tålmodige investor II" bør handle om Genmab investorere. :-)
| |
30/4 11:40 af royal |
"Vi anbefaler, at investorerne stille og
roligt begynder at stige ombord på toget, inden det kører." Zzzzzzzzzzzzzzzzzzz
| |
30/4 11:09 af E L |
jyskebank monthly
(link)
| |
30/4 10:56 af lahn1 |
wise guy ;-)
| |
30/4 10:38 af E L |
the strength of the competition will greatly affect epco sales, it will be a battle
| |
30/4 10:37 af E L |
Take your pick ;-)
| |
30/4 10:36 af E L |
Jefferies analysts previously predicted Epkinly could reach about $2.75 billion in peak sales.
| |
30/4 10:36 af E L |
Drug: Epcoritamab
Companies: AbbVie and Genmab
Used for: Lymphoma
Est. 2028 sales: $1.7 billion (link)
| |
30/4 10:34 af E L |
Sydbank epcoritamab
He estimates the new drug’s annual peak sales potential at USD 3.5bn.(link)
| |
| ||
30/4 10:33 af E L |
Due to Epkinly's tremendous efficacy, analysts at SVB Securities think that the drug could reach peak annual sales of $3 billion in the U.S. (link)
| |
30/4 10:33 af E L |
'GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027, with global sales expected to exceed $1.9bn by 2029.' from may last year (link)
| |
30/4 10:21 af GeorgeBest |
Thanks E L 09:48. Can you also see what’s the forecast for epcoritamab is by 2030?
| |
30/4 09:34 af Riis7 |
Og fcm:-)
| |
30/4 09:32 af Bullish |
OB og Genmab har noget til fælles for tiden..
| |
30/4 08:51 af E L |
i am sure we will still all be here in 2030 to see if that comes true, whilst complaining about the share price ;-)
| |
30/4 08:49 af E L |
||
30/4 08:48 af E L |
Tivdak seems to go a little bit under the radar, but 'According to GlobalData’s patient-based forecast, Tivdak is forecast to generate sales of $1.4bn in the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada) by 2030'
| |
30/4 08:47 af E L |
This full approval is the minimum requirement to continue with Tivdak and therefore an important step. It will depend on how much new owner Pfizer sees in the drug, but the EMA application and current conversations with regulators to continue also in head and neck cancer bode well for now.
| |
30/4 08:44 af w |
Komplet uforståeligt at den kan falde på en godkendelse, der iøvrigt kom før tid
| |
30/4 08:44 af royal |
Lige før man håber på et dårligt Q1 på torsdag.
| |
30/4 08:32 af Vitus |
Vor herre bev……
| |
30/4 08:18 af w |
Alt er indregnet;)
| |
30/4 08:17 af Vitus |
Betyder det noget…..
| |
30/4 08:03 af lahn1 |
Dejligt med endnu en god nyhed :-)
| |
30/4 07:59 af E L |
nicely on time, PDUFA goal date was May 9
| |
30/4 07:08 af JKY_VH |
Argh, det er vel ikke så stor en overraskelse, at det slår bunden ud af aktien;-)
| |
30/4 05:58 af royal |
Spændende hvad det koster på kursen. :-)
| |
30/4 05:56 af transalp |
Go morgen.. :)
| |
30/4 05:51 af ProInvestorNEWS |
Genmab og partner henter fuld amerikansk godkendelse til livmoderhalskræftmiddel (link)
| |
30/4 05:36 af Stroka |
og tak for en god nyhed. :-)
| |
30/4 05:36 af bibob |
God morgen. :-)
| |
30/4 05:36 af Stroka |
God morgen :-)
| |
30/4 05:08 af Helge Larsen/PI-redaktør |
Godmorgen :-)
| |
30/4 04:34 af JKY_VH |
Tak for det og god morgen;-)
| |
30/4 04:22 af Budweis |